In vitro efficacy of a buffered chelating solution as an antimicrobial potentiator for antifungal drugs against fungal pathogens obtained from horses with mycotic keratitis

American Journal of Veterinary Research

Volumn 67, Issue 4, 2006, Pages 562-568

  Weinstein, William L ^a   Moore, Phillip A ^a   Sanchez, Susan ^a   Dietrich, Ursula M ^a   Wooley, Richard E ^a   Ritchie, Branson W ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CHELATING AGENT; EDETIC ACID DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NATAMYCIN; TRICIDE; TROMETAMOL;

ANTIFUNGAL ACTIVITY; ARTICLE; CLADOSPORIUM; CONTROLLED STUDY; CURVULARIA; DRUG EFFICACY; DRUG POTENTIATION; FUNGAL STRAIN; FUNGUS ISOLATION; FUSARIUM; GROWTH INHIBITION; HORSE; HORSE DISEASE; IN VITRO STUDY; KERATOMYCOSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIUM; QUALITY CONTROL; REFERENCE VALUE; STRAIN DIFFERENCE; TREATMENT OUTCOME; ANIMAL; ANIMAL DISEASE; COMPARATIVE STUDY; KERATITIS; MICROBIOLOGY; MYCOSIS; SOLUTION AND SOLUBILITY;

ASPERGILLUS; CANDIDA ALBICANS; CLADOSPORIUM; CURVULARIA; EQUIDAE; FUNGI; FUSARIUM; PAECILOMYCES VARIOTII; PENICILLIUM;

ANIMALS; ANTIFUNGAL AGENTS; CHELATING AGENTS; DRUG SYNERGISM; HORSE DISEASES; HORSES; ITRACONAZOLE; KERATITIS; KETOCONAZOLE; MICONAZOLE; MYCOSES; NATAMYCIN; SOLUTIONS;

EID: 33646845818     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.4.562     Document Type: Article

References (47)

1. Andrew SE, Nguyen A, Jones GL, et al. Seasonal effects on the aerobic bacterial and fungal conjunctival flora of normal thoroughbred brood mares in Florida. Vet Ophthalmol 2003;6:45-50.
2. Barton MH. Keratomycosis. Compend Contin Educ Pract Vet 1992;14:936-944.
3. Gaarder, JE, Rebhun WC, Ball MA, et al. Clinical appearances, healing patterns, risk factors, and outcomes of horses with fungal keratitis: 53 cases (1978-1996). J Am Vet Med Assoc 1998;213:105-112.
4. Gugnani HC, Gupta S, Talwar RS. Role of opportunistic fungi in ocular infections in Nigeria. Mycopathologia 1978,65:155-166.
5. Thomas PA. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev 2003;16:730-797.
6. Gemensky-Metzler AJ, Wilkie DA, Kowalski JJ, et al. Changes in bacterial and fungal ocular flora of clinically normal horses following experimental application of topical antimicrobial or antimicrobial-corticosteroid ophthalmic preparations. Am J Vet Res 2005;66:800-811.
7. Moore CP, Heller N, Majors LJ, et al. Prevalence of ocular microorganisms in hospitalized and stabled horses. Am J Vet Res 1988;49:773-777.
8. Rosa M, Cardozo LM, da Silva Pereira J, et al. Fungal flora of normal eyes of healthy horses from the state of Rio de Janeiro, Brazil. Vet Ophthalmol 2003;6:51-55.
9. Andrew SE, Willis MA. Diseases of the cornea and sclera. In: Gilger BC, ed. Equine ophthalmology. St Louis: Elsevier Saunders, 2004;157-251.
10. Beech J, Sweeney CR. Keratomycosis in 11 horses. Equine Vet J Suppl 1983;2:39-44.
11. Brooks DE. Equine ophthalmology In: Gelatt KN, ed. Veterinary ophthalmology. 3rd ed. Baltimore: Lippincott, Williams & Wilkins, 1999;1053-1116.
12. Andrew SE, Brooks DE, Smith PJ, et al. Equine ulcerative keratomycosis: visual outcome and ocular survival in 39 cases (1987-1996). Equine Vet J 1998;30:109-116.
13. Ball MA, Rebhun WC, Gaarder JE, et al. Evaluation of itraconazole-dimethyl sulfoxide ointment for treatment of keratomycosis in nine horses. J Am Vet Med Assoc 1997;211:199-203.
14. Brooks DE, Andrews SE, Dillavou CL, et al. Antimicrobial susceptibility patterns of fungi isolated from horses with ulcerative keratomycosis. Am J Vet Res 1998;59:138-142.
15. Coad CT, Robinson NM, Wilhelmus KR. Antifungal sensitivity testing for equine keratomycosis. Am J Vet Res 1985;46:676-678.
16. Grahn B. Equine keratomycosis: clinical and laboratory findings in 23 cases. Prog Vet Comp Ophthalmol 1993;3:2-7.
17. Moore CP, Fales WH, Whittington P, et al. Bacterial and fungal isolates from equidae with ulcerative keratitis. J Am Vet Med Assoc 1983;182:600-603.
18. Leck AK, Thomas PA, Hagan M, et al. Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. Br J Ophthalmol 2002;86:1211-1215.
19. Mauger TF. Antimicrobials. In: Mauger TF, Craig EL, eds. Havener's ocular pharmacology. 6th ed. St Louis: Mosby-Year Book Inc, 1994;234-349.
20. Yolton DP. Antiinfective drugs. In: Bartlet JD, Siret SD, eds. Clinical ocular pharmacology. 4th ed. Woburn, Mass: Butterworth-Heinemann, 2004;219-298.
21. Mathis GA. Clinical ophthalmic pharmacology and therapeutics. In: Gelatt KN, ed. Veterinary ophthalmology. 3rd ed. Baltimore: Lippincott, Williams & Wilkins, 1999;291-354.
22. Ashworth CD, Nelson DR. Antimicrobial potentiation of irrigation solutions containing tris-(hydroxymethyl) aminomethane-EDT. J Am Vet Med Assoc 1990;197:1513-1514.
23. Blue JL, Wooley RE, Eagon RG. Treatment of experimentally induced Pseudomonas aeruginosa otitis externa in the dog by lavage with EDTA-tromethamine-lysozyme. Am J Vet Res 1974; 35:1221-1223.
24. Farca AM, Piromalli G, Maffei F, et al. Potentiating effect of EDTA-Tris on the activity of antibiotics against resistant bacteria associated with otitis, dermatitis and cystitis. J Small Anim Pract 1997;38:243-245.
25. Sparks TA, Kemp DT, Wooley RE, et al. Antimicrobial effect of combinations of EDTA-Tris and amikacin or neomycin on the microorganisms associated with otitis externa in dogs. Vet Res Commun 1994;18:241-249.
26. Wooley RE, Jones MS. Action of EDTA-Tris and antimicrobial agent combinations on selected pathogenic bacteria. Vet Microbiol 1983;8:271-280.
27. Wooley RE, Ritchie BW, Burnley VV, et al. Antibiotic resistance: seeking a solution. Vet Forum 2004;21:36-43.
28. Foster AP, DeBoer DJ. Tri EDTA crystals and aqueous. Compend Contin Educ Pract Vet 1998;20:909-918.
29. Bjorling DE, Wooley RE. EDTA-tromethamine lavage as an adjunct treatment for multiple fistulas in a dog. J Am Vet Med Assoc 1982;181:596-597.
30. Wooley RE, Berman AP, Shotts EB. Antibiotic-tromethamine-EDTA lavage for the treatment of bacterial rhinitis in a dog. J Am Vet Med Assoc 1979;175:817-818.
31. Wooley RE, Schall WD, Eagon RG, et al. Efficacy of EDTA-trislysozyme lavage in the treatment of experimentally in induced Pseudomonas aeruginosa cystitis in the dog. Am J Vet Res 1974;35:27-29.
32. Younquist RS, Blanchard TL, Lapin D, et al. The effects of EDTA-tris infusion on the equine endometrium. Theriogenology 1984;22:593-599.
33. Wooley RE, Ritchie BW, Kemp DT, et al. In vitro evaluation of the antimicrobial effect of commercially available mastitis medications combined with EDTA-tris on bacteria that cause mastitis in cattle. Vet Ther 2002;2:150-156.
34. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing for yeasts. Approved standard document M27-A2. 2nd ed. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2002.
35. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard document M38-A. Wayne, Pa; National Committee for Clinical Laboratory Standards, 2002.
36. de Hoog GS, Guarro J, Gené J, et al. General techniques. In: de Hoog GS, Guarro J, Gené J, et al, eds. Atlas of clinical fungi. 2nd ed. Utrecht, the Netherlands: Centraalbureau voor Schimmelcultures/ Universitat Rovira i Virgili, 2000;39-53.
37. Sutton DA, Fothergill AW, Rinaldi MG. Introduction. In: Sutton DA, Fothergill AW, Rinaldi MG, eds. Guide to clinically significant fungi. Baltimore: The Williams & Wilkins Co, 1998;9-11.
38. Aguilar C, Pujol I, Sala J, et al. Antifungal susceptibilities of Paecilomyces species. Antimicrob Agents Chemother 1998; 42:1601-1604.
39. Marco F, Pfaller MA, Messer SA, et al. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol 1998;36:433-436.
40. Marcilla A, Valentin E, Sentandreu R. The cell wall structure: developments in diagnosis and treatment of candidiasis. Int Microbiol 1998;1:107-116.
41. Arikan S, Lozano-Chiu M, Paetznick V, et al. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 1999;37:3946-3951.
42. Pujol I, Guarro J, Gené J, et al. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother 1997;39:163-167.
43. WHO food additives series: safety evaluation of certain food additives and contaminants. Natamycin (pimaricin). Available at: www.inchem.org/documents/jecfa/jecmono/v48jeo6.htm. Accessed May 27, 2005.
44. Tawara SF, Ikeda K, Maki Y, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000;44:57-62.
45. Wildfeuer A, Seidl HP, Paule I, et al. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 1998;41:309-319.
46. Guarro J, Llop C, Aguilar C, et al. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of filamentous fungi. Antimicrob Agents Chemother 1997;41:2760-2762.
47. Guarro J, Akib T, Horta RA, et al. Mycotic keratitis due to Curvularia senegalensis and in vitro antifungal susceptibilities of Curvularia spp. J Clin Microbiol 1999;37:4170-4173.